TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31686981

Group type: EXPERIMENTAL
Intervention: Blood lipid indicators (BLIs) including triglyceride (TG) level, TG/high-density lipoprotein cholesterol (HDL-C) ratio, and total cholesterol (TC)/HDL-C ratio.
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Blood lipid indicators (BLIs) correlated to insulin resistance (IR).
Number of subjects: 969

Group type: EXPERIMENTAL
Intervention: Combination of indicators with diagnostic value for IR.
Number of subjects: 969
Study: 29888275

Group type: EXPERIMENTAL
Intervention: Azilsartan (Azil) as add-on treatment with Methotrexate (MTX) for 90 days
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo with Methotrexate (MTX) for 90 days
Number of subjects: 64
Study: 25957615

Group type: EXPERIMENTAL
Intervention: Heated humidification (HH) with heated breathing tube
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Heated humidification (HH)
Number of subjects: 72

Group type: COMPARATOR
Intervention: No heated humidification (Control)
Number of subjects: 72
Study: 24471516

Group type: EXPERIMENTAL
Intervention: Indoor intermittent training program (3 sessions of 60 min/week for 12 weeks)
Number of subjects: 105
Study: 22035805

Group type: EXPERIMENTAL
Intervention: XEN402 (400mg twice daily)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 20705157

Group type: EXPERIMENTAL
Intervention: 3 mg DRSP/30 mcg EE (Yasmin)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2 mg CMA/30 mcg EE (Belara)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 75 mcg GSD/30 mcg EE (Minulet)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 150 mcg DSG/30 mcg EE (Practil 21)
Number of subjects: 40
Study: 17400976

Group type: EXPERIMENTAL
Intervention: Immediate‐release oxycodone 5 mg and acetaminophen 325 mg (Percocet‐5) four times daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Controlled‐release oxycodone 10 mg (OxyContin) every 12 hr and placebo twice daily
Number of subjects: 120
Study: 16267322

Group type: EXPERIMENTAL
Intervention: Natalizumab 300 mg at weeks 0, 4, and 8
Number of subjects: 1244

Group type: COMPARATOR
Intervention: Placebo at weeks 0, 4, and 8
Number of subjects: 1244

Group type: EXPERIMENTAL
Intervention: Natalizumab 300 mg every four weeks through week 56
Number of subjects: 1244

Group type: COMPARATOR
Intervention: Placebo every four weeks through week 56
Number of subjects: 1244
Study: 12122550

Group type: EXPERIMENTAL
Intervention: Obese women
Number of subjects: 83

Group type: COMPARATOR
Intervention: Reference women
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 83
Study: 10523328

Group type: EXPERIMENTAL
Intervention: Weight loss induced by 12 weeks of caloric restriction in obese hypertensive men
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Weight loss induced by 12 weeks of caloric restriction in obese normotensive men
Number of subjects: 75
Study: 7880708

Group type: EXPERIMENTAL
Intervention: 51W89 (80 micrograms kg-1)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 51W89 (incremental doses of 94 (19) micrograms kg-1)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: 51W89
Number of subjects: 68
Study: 1920787

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of buprenorphine at 0.2 mg.24 hr‐1
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of pethidine at 50 mg.hr‐1
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 20
Study: 6811447

Group type: EXPERIMENTAL
Intervention: procetofen (300‐600 mg daily) for 6 months
Number of subjects: 33
Study: 30667285

Group type: EXPERIMENTAL
Intervention: Culturally Adapted Treatment (CAT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard Evidence-Based Treatment (EBT)
Number of subjects: 61
Study: 31220121

Group type: EXPERIMENTAL
Intervention: Cognitive dual task gait training (CDTT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Motor dual task gait training (MDTT)
Number of subjects: 18

Group type: COMPARATOR
Intervention: General gait training (control)
Number of subjects: 18
Study: 29313875

Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 145

Group type: COMPARATOR
Intervention: Psychosocial intervention
Number of subjects: 145

Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 145
Study: 26757463

Group type: EXPERIMENTAL
Intervention: Frozen Fecal Microbiota Transplantation (FMT)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Fresh Fecal Microbiota Transplantation (FMT)
Number of subjects: 232
Study: 22915624

Group type: EXPERIMENTAL
Intervention: Intravenous abatacept (∼10 mg/kg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 21505147

Group type: EXPERIMENTAL
Intervention: Metreleptin (0.08 mg·kg(‐1)·day(‐1) for 10 wk)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Metreleptin (initial dose: 0.08 mg·kg(‐1)·day(‐1) for 3 mo, increased to 0.12 mg·kg(‐1)·day(‐1) if menstruation did not occur)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 18351303

Group type: EXPERIMENTAL
Intervention: 0.5% levobupivacaine
Number of subjects: 88

Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 88

Group type: COMPARATOR
Intervention: 0.75% ropivacaine
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 0.125% levobupivacaine
Number of subjects: 88

Group type: COMPARATOR
Intervention: 0.125% bupivacaine
Number of subjects: 88

Group type: COMPARATOR
Intervention: 0.2% ropivacaine
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Intraoperative anesthesia demand
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Safety parameters
Number of subjects: 88
Study: 16849930

Group type: EXPERIMENTAL
Intervention: Ginseng
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14687826

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 40
Study: 10741768

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9333110

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day orally for 10 days)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Perphenazine (0.11 mg/kg orally) after paroxetine pretreatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8471404

Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg day‐1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg day‐1)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3780837

Group type: EXPERIMENTAL
Intervention: Torasemide
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 6
Study: 28958082

Group type: EXPERIMENTAL
Intervention: Physical activity promoting intervention (multicomponent, individually tailored; includes group sessions, individual exercise, serious games training, competence training for staff)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Physical activity promoting intervention
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 143
Study: 26657657

Group type: EXPERIMENTAL
Intervention: BEV-CAP
Number of subjects: 277
Study: 24614125

Group type: EXPERIMENTAL
Intervention: Serum citrulline (CIT)
Number of subjects: 26
Study: 22306121

Group type: EXPERIMENTAL
Intervention: Ranibizumab treated-initial (n=600)
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: Ranibizumab treated-XO (n=190)
Number of subjects: 853

Group type: COMPARATOR
Intervention: Ranibizumab untreated (n=63)
Number of subjects: 853
Study: 19921204

Group type: EXPERIMENTAL
Intervention: Reconstruction setting A (1 mm section thickness, soft kernel)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Reconstruction setting B (2 mm section thickness, soft kernel)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Reconstruction setting C (2 mm section thickness, sharp kernel)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Comparison of settings A and C to setting B
Number of subjects: 200
Study: 19066233

Group type: EXPERIMENTAL
Intervention: Walking routes (n = 19)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Walking while working (n = 25)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both walking interventions pooled (n = 44)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Active group (> 10,000 steps/day, n = 21)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Moderately Active group (7500-9999, n = 11)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Sedentary-Low activity group
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Initially low active participants
Number of subjects: 70
Study: 18190629

Group type: EXPERIMENTAL
Intervention: Variable dosage of sildenafil (25, 50, 100 mg) or vardenafil (5, 10, 20 mg) determined by NPTR
Number of subjects: 154

Group type: COMPARATOR
Intervention: Fixed low-dose sildenafil 25 mg or vardenafil 5 mg
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Variable dosage of sildenafil or vardenafil
Number of subjects: 154

Group type: COMPARATOR
Intervention: Fixed low-dose sildenafil or vardenafil
Number of subjects: 154
Study: 14748034

Group type: EXPERIMENTAL
Intervention: gamma frailty model
Number of subjects: 0
Study: 11305719

Group type: EXPERIMENTAL
Intervention: Noncatheter-related thrombosis in children with underlying disorders
Number of subjects: 95
Study: 9165187

Group type: EXPERIMENTAL
Intervention: Dietary intervention (low-saturated-fat, low-cholesterol, high-carbohydrate diet)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control group (standard diet)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Intervention fathers
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Intervention mothers
Number of subjects: 148

Group type: COMPARATOR
Intervention: Control parents
Number of subjects: 148
Study: 7659137

Group type: EXPERIMENTAL
Intervention: Flutrimazole 1% dermal cream
Number of subjects: 484

Group type: COMPARATOR
Intervention: Clotrimazole 1% dermal cream
Number of subjects: 484
Study: 3499502

Group type: EXPERIMENTAL
Intervention: Sulbactam and ampicillin (SA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Metronidazole and cefotaxime (MC)
Number of subjects: 100
Study: 30890314

Group type: EXPERIMENTAL
Intervention: Bidirectional knotless barbed suture (group A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Polyglactin suture (group B)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Total surgery time (both groups)
Number of subjects: 70
Study: 30280800

Group type: EXPERIMENTAL
Intervention: TA + TNR
Number of subjects: 4

Group type: COMPARATOR
Intervention: TA ‐ TNR
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: TA + TR
Number of subjects: 4

Group type: COMPARATOR
Intervention: TA ‐ TR
Number of subjects: 4
Study: 26888731

Group type: EXPERIMENTAL
Intervention: Allogeneic-adipose-derived mesenchymal stem cells (ALLO-ASCs) injected into the anal sphincter (doses: 3 × 10(7), 6 × 10(7), 9 × 10(7) cells)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0.9% normal saline injection mixed with fibrin glue (placebo)
Number of subjects: 0
Study: 25075802

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT) delivered by a child anxiety specialist in the primary care clinic
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Therapist-supported bibliotherapy (implemented by the parent with therapist support by telephone)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Both modalities (CBT and therapist-supported bibliotherapy)
Number of subjects: 48
Study: 23101118

Group type: EXPERIMENTAL
Intervention: Tight glucose control (TGC)
Number of subjects: 569

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 569
Study: 20586997

Group type: EXPERIMENTAL
Intervention: Preterm adolescents
Number of subjects: 391

Group type: COMPARATOR
Intervention: Term controls
Number of subjects: 391
Study: 17096196

Group type: EXPERIMENTAL
Intervention: SAMHSA Model Program keepin' it REAL (prevention program)
Number of subjects: 1364
Study: 15754236

Group type: EXPERIMENTAL
Intervention: Therapeutic practice muscle strengthening program (TG1)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Health club muscle strengthening program (TG2)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Gymnastic group muscle strengthening program (TG3)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 102
Study: 12047050

Group type: EXPERIMENTAL
Intervention: Visual presentation of verbal material in serial recall tasks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Auditory presentation of verbal material in serial recall tasks
Number of subjects: 0
Study: 10452168

Group type: EXPERIMENTAL
Intervention: Experimental bone lesions created in the alveolar crest of a skull, assessed using standardized periapical radiographs before and after defect creation.
Number of subjects: 5

Group type: COMPARATOR
Intervention: Standardized periapical radiographs obtained before and after the defects were made.
Number of subjects: 5
Study: 7615189

Group type: EXPERIMENTAL
Intervention: Mesalamine (1.5 g twice a day)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 2565158

Group type: EXPERIMENTAL
Intervention: Bevantolol
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Bevantolol combined with hydrochlorothiazide
Number of subjects: 21

Group type: COMPARATOR
Intervention: Hydrochlorothiazide
Number of subjects: 21
Study: 823950

Group type: EXPERIMENTAL
Intervention: Thyrotropin releasing hormone (TRH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30321962

Group type: EXPERIMENTAL
Intervention: Scarf osteotomy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Long chevron osteotomy
Number of subjects: 48
Study: 28949074

Group type: EXPERIMENTAL
Intervention: Whey + high-MCFAs
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: High-MCFAs (independently of protein type)
Number of subjects: 52
Study: 25989154

Group type: EXPERIMENTAL
Intervention: TEAS (transcutaneous electric acupoint stimulation) group (n=31)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (n=32)
Number of subjects: 63
Study: 23815739

Group type: EXPERIMENTAL
Intervention: SMART Arm training with OT-stim and usual therapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: SMART Arm training without OT-stim and usual therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Usual therapy alone
Number of subjects: 75
Study: 21084162

Group type: EXPERIMENTAL
Intervention: Paresthesic SCS (group PS; n=10)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Subliminal SCS (group SS; n=7)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham SCS (group NS; n=8)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Paresthesic SCS (group PS)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Subliminal SCS (group SS)
Number of subjects: 25
Study: 18931330

Group type: EXPERIMENTAL
Intervention: FeNO0.05 plus symptom monitoring
Number of subjects: 151

Group type: COMPARATOR
Intervention: Monitoring of symptoms only
Number of subjects: 151
Study: 17332127

Group type: EXPERIMENTAL
Intervention: Vastus-splitting approach
Number of subjects: 42

Group type: COMPARATOR
Intervention: Median parapatellar approach
Number of subjects: 42
Study: 15121746

Group type: EXPERIMENTAL
Intervention: Sodium chloride (NaCl) as the iontophoresis vehicle for ACh
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sodium chloride (NaCl) as the iontophoresis vehicle for SNP
Number of subjects: 14

Group type: COMPARATOR
Intervention: Deionized water as the iontophoresis vehicle for ACh
Number of subjects: 14

Group type: COMPARATOR
Intervention: Deionized water as the iontophoresis vehicle for SNP
Number of subjects: 14
Study: 14991292

Group type: EXPERIMENTAL
Intervention: Computer-assisted balance training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Home-based exercise program
Number of subjects: 24
Study: 11757182

Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy (IF-RT)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Extended-field radiotherapy (EF-RT)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Total lymphatic irradiation (TLI)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Radiotherapy doses of 26-34 Gy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Radiotherapy doses of 36 Gy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Radiotherapy doses of 40 Gy or more
Number of subjects: 47
Study: 9221383

Group type: EXPERIMENTAL
Intervention: Bleomycin (BMC)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Mitoxantrone (MIT)
Number of subjects: 102
Study: 8214404

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 76
Study: 3039831

Group type: EXPERIMENTAL
Intervention: Nabilone (N) + Dexamethasone (DXM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nabilone (N) alone
Number of subjects: 40
Study: 28734971

Group type: EXPERIMENTAL
Intervention: Robotic system
Number of subjects: 36

Group type: COMPARATOR
Intervention: Laparoscopic approach
Number of subjects: 36
Study: 26374339

Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Bag-Mask Ventilation (BMV)
Number of subjects: 0
Study: 25794092

Group type: EXPERIMENTAL
Intervention: Simethicone (200 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no simethicone)
Number of subjects: 80
Study: 23926275

Group type: EXPERIMENTAL
Intervention: Disruption of dorsolateral prefrontal cortex (DLPFC) function
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disruption of ventrolateral prefrontal cortex (VLPFC) function
Number of subjects: 0
Study: 21147298

Group type: EXPERIMENTAL
Intervention: Low concentration (LC) contrast medium (150 mg iodine/ml)
Number of subjects: 95

Group type: COMPARATOR
Intervention: High concentration (HC) contrast medium (300 mg iodine/ml)
Number of subjects: 95
Study: 18942560

Group type: EXPERIMENTAL
Intervention: Audiovisual support in adjunct to written informative form
Number of subjects: 0

Group type: COMPARATOR
Intervention: Written informative form only
Number of subjects: 0
Study: 16141380

Group type: EXPERIMENTAL
Intervention: Heart failure patients
Number of subjects: 9
Study: 12701664

Group type: EXPERIMENTAL
Intervention: Errorless learning
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional trial-and-error instruction
Number of subjects: 54
Study: 10949003

Group type: EXPERIMENTAL
Intervention: Carbohydrate (C)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 15
Study: 8839907

Group type: EXPERIMENTAL
Intervention: Carboplatin/5-fluorouracil concurrent with radiotherapy (group I)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Radiotherapy alone (historical control group II)
Number of subjects: 74
Study: 1467206

Group type: EXPERIMENTAL
Intervention: Discrete scale (DS)
Number of subjects: 849

Group type: COMPARATOR
Intervention: Visual analogue scale (VAS)
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Continuous chromatic analogue scale (ACCS)
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Quantity (Q)
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Entity (E)
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Maximal Intensity (MI)
Number of subjects: 849
Study: 6370157

Group type: EXPERIMENTAL
Intervention: Prophylactic administration of 4 units of platelet concentrates at the end of bypass
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (not receiving platelet concentrates)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Prophylactic administration of platelet concentrates
Number of subjects: 28
Study: 31481568

Group type: EXPERIMENTAL
Intervention: Systematic medication review intervention using the 'Systematic Tool to Reduce Inappropriate Prescribing'‐Assistant (STRIPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care sham intervention (GP discusses medication list completeness)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systematic medication review intervention
Number of subjects: 0
Study: 29489977

Group type: EXPERIMENTAL
Intervention: G‐CSF injection for 3 days after chemotherapy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 100
Study: 26458034

Group type: EXPERIMENTAL
Intervention: Generic glatiramer acetate (20 mg)
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Brand glatiramer acetate (20 mg)
Number of subjects: 794

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 794
Study: 23842212

Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (IFNB-1b)
Number of subjects: 468

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study: 22480437

Group type: EXPERIMENTAL
Intervention: Pilates based core stability training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardised physiotherapy exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Contract-relax relaxation sessions (placebo control)
Number of subjects: 0
Study: 19490266

Group type: EXPERIMENTAL
Intervention: VT induced by 1 or 2 VES or burst pacing (single VES n = 15, double VES n = 127, burst n = 7, total n = 149)
Number of subjects: 371

Group type: COMPARATOR
Intervention: VT induced by 3 VES (n = 222)
Number of subjects: 371
Study: 17516858

Group type: EXPERIMENTAL
Intervention: High-vegetable dietary intervention
Number of subjects: 1156

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 1156
Study: 15161434

Group type: EXPERIMENTAL
Intervention: Gemcitabine (Gemzar®) as a single agent
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine in combination with platinum-based chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gemcitabine in combination with radiotherapy
Number of subjects: 0
Study: 12075638

Group type: EXPERIMENTAL
Intervention: IV ephedrine infusion (5 mg.min(‐1) immediately after spinal injection)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Bolus administration of IV ephedrine (10 mg in case of hypotension)
Number of subjects: 30
Study: 10458204

Group type: EXPERIMENTAL
Intervention: Docetaxel at 100 mg/m2 administered as a 1-hour intravenous infusion every 3 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel at 100 mg/m2 or 75 mg/m2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control regimen of vinorelbine or ifosfamide
Number of subjects: 0